Literature DB >> 11521209

Audiometric abnormalities in children with Gaucher disease type 3.

D E Bamiou1, P Campbell, A Liasis, J Page, T Sirimanna, S Boyd, A Vellodi, C Harris.   

Abstract

Exogenous enzyme replacement therapy achieves satisfactory biomedical correction in Gaucher type 1 disease and may halt or reverse neurological progression in type 3, while it does not appear to influence the outcome in type 2. In view of the therapeutic possibilities, early detection and monitoring of type 3 Gaucher disease, as well as evaluation of the effectiveness of enzyme therapy on neuronopathic involvement is necessary. The objective of this study was to evaluate the extent of brainstem disease in children with proven Gaucher type 3, by means of an audiological test battery. We studied 9 patients with Gaucher type 3 disease. The tests included baseline audiometric tests, as well as auditory brainstem evoked responses (ABR), acoustic reflexes and medial olivo-cochlear suppression by contralateral noise tests, that involve overlapping but not identical efferent and afferent pathways and brainstem structures. We found a constellation of abnormalities including bilaterally raised acoustic reflexes, poor medial olivo-cochlear suppression, and very poor brainstem evoked potentials. These abnormalities could be due to a single lesion in the dorsomedial brainstem, or to multiple lesions, and further study is needed to clarify this issue. Combined audiological tests may provide information on the severity of the neurological involvement and should therefore be part of a standard assessment for the diagnosis as well as for long term neurological monitoring of Gaucher type 3 patients.

Entities:  

Mesh:

Year:  2001        PMID: 11521209     DOI: 10.1055/s-2001-16611

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  8 in total

Review 1.  Neuropathic Gaucher disease.

Authors:  Gregory M Pastores
Journal:  Wien Med Wochenschr       Date:  2010-12

Review 2.  Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring.

Authors:  Antonio Baldellou; Generoso Andria; Pauline E Campbell; Joel Charrow; Ian J Cohen; Gregory A Grabowski; Chris M Harris; Paige Kaplan; Kieran McHugh; Eugen Mengel; Ashok Vellodi
Journal:  Eur J Pediatr       Date:  2003-12-16       Impact factor: 3.183

Review 3.  Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements.

Authors:  Gregory A Grabowski; Generoso Andria; Antonio Baldellou; Pauline E Campbell; Joel Charrow; Ian J Cohen; Chris M Harris; Paige Kaplan; Eugen Mengel; Miguel Pocovi; Ashok Vellodi
Journal:  Eur J Pediatr       Date:  2003-12-16       Impact factor: 3.183

4.  Evoked potentials and neurocognitive functions in pediatric Egyptian Gaucher patients on enzyme replacement therapy: a single center experience.

Authors:  Azza Abdel Gawad Tantawy; Eman Mounir Sherif; Amira Abdel Moneam Adly; Sahar Hassanine; Amina Hafez Awad
Journal:  J Inherit Metab Dis       Date:  2013-03-19       Impact factor: 4.982

5.  Hearing loss in Pompe disease revisited: results from a study of 24 children.

Authors:  Carine I van Capelle; Andre Goedegebure; Nienke C Homans; Hans L J Hoeve; Arnold J Reuser; Ans T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2010-07-02       Impact factor: 4.982

6.  Hearing in adults with Pompe disease.

Authors:  Nadine A M E van der Beek; Hans Verschuure; Arnold J J Reuser; Ans T van der Ploeg; Pieter A van Doorn; René M L Poublon
Journal:  J Inherit Metab Dis       Date:  2011-10-15       Impact factor: 4.982

Review 7.  Molecular Mechanisms and Biological Functions of Autophagy for Genetics of Hearing Impairment.

Authors:  Ken Hayashi; Yuna Suzuki; Chisato Fujimoto; Sho Kanzaki
Journal:  Genes (Basel)       Date:  2020-11-11       Impact factor: 4.096

8.  Hearing loss in children with Fabry disease.

Authors:  E Suntjens; W A Dreschler; J Hess-Erga; R Skrunes; F A Wijburg; G E Linthorst; C Tøndel; M Biegstraaten
Journal:  J Inherit Metab Dis       Date:  2017-05-31       Impact factor: 4.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.